EUVIMEDEUVIMED entdecken
Crossref

Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile

Holiness S A Olasore, Joseph O Faleti, Taiwo O Afe, Abdullahi A Murtala, Matthew O Olawale, Abdur-Rasheed B Awesu, Miriam N Igwo-Ezikpe, Olubunmi A Magbagbeola, Anthony A Olashore

Schizophrenia Research · 2025

DOI: 10.1016/j.schres.2025.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Research, 2025. Verfasst von Holiness S A Olasore und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine of the University of Lagos, Idi-Araba Campus, Lagos, Nigeria. Electronic address: holashore@unilag.ed…. Hauptthemen laut MEDLINE: Receptors, Dopamine D2, Risperidone, Blood Glucose, Antipsychotic Agents. Die Arbeit nennt 59 Literaturangaben. Gefördert von: University of Lagos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are indications that the transient blockade of the dopamine receptor D2 (DRD2) by atypical antipsychotics such as risperidone is related to their metabolic side effects. We, therefore, examined the relationship between TaqIA polymorphism of the DRD2 gene and acute risperidone-induced metabolic changes. We recruited 153 newly diagnosed patients with psychotic disorders (71 males and 82 females) from the Federal Neuropsychiatric Hospital, Yaba, Lagos, Nigeria. Body weight, fasting blood glucose (FBG), triglycerides (TG), total cholesterol (TChol), low-density lipoprotein cholesterol (LDLChol), and high-density lipoprotein cholesterol (LDLChol) were all determined at baseline and the end of 6 weeks of administration of risperidone (2 mg twice daily). DNA was also extracted from peripheral blood, and genotyping was carried out using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The relationship between the mean changes in the metabolic indices and the DRD2 TaqIA genotype was statistically determined. The frequencies of the A1A1, A1A2, and A2A2 were 0.229, 0.412, and 0.360, respectively. However, the population was not in Hardy-Weinberg equilibrium (χ2 = 4.023, p < 0.01). The mean weight change and the mean changes in FBG, TG, TChol, and LDLChol were significantly (p < 0.05) higher among participants with the A1A1 genotype, followed by the heterozygous (A1A2) participants and lowest among those homozygous for the A2 allele. However, there was no significant difference in the mean change in HDLChol across all genotype groups. The DRD2 TaqIA1 allele is associated with higher risperidone-induced weight gain and metabolic changes among Nigerians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Dopamine D2RisperidoneBlood GlucoseAntipsychotic AgentsBody WeightLipidsPsychotic DisordersHumansMaleFemaleAdultYoung AdultMiddle AgedGenotypePolymorphism, GeneticNigeriaAdolescentGene Frequency

Stichwörter der Autor:innen

Dopamine receptorGene polymorphismMetabolic adverse effectsRisperidone

Substanzen

Receptors, Dopamine D2RisperidoneDRD2 protein, humanBlood GlucoseAntipsychotic AgentsLipids

Autor:innen und Institutionen

  • Department of Biochemistry, College of Medicine of the University of Lagos, Idi-Araba Campus, Lagos, Nigeria. Electronic address: holashore@unilag.edu.ng.
  • Department of Biochemistry, College of Medicine of the University of Lagos, Idi-Araba Campus, Lagos, Nigeria.
  • Department of Medicine, Faculty of Clinical Sciences, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Ogun State, Nigeria.
  • Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Ogun State, Nigeria.
  • Federal Neuropsychiatric Hospital, Yaba, Lagos, Nigeria.
  • Department of Psychiatry, University of Botswana, Gaborone, Botswana.

Förderung

  • University of Lagos

Zitieren

APA

Olasore, H. S. A., Faleti, J. O., Afe, T. O., Murtala, A. A., Olawale, M. O., Awesu, A. B., Igwo-Ezikpe, M. N., Magbagbeola, O. A., & Olashore, A. A. (2025). Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile. Schizophrenia Research. https://doi.org/10.1016/j.schres.2025.03.005

Vancouver

Olasore HSA, Faleti JO, Afe TO, Murtala AA, Olawale MO, Awesu AB, et al. Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile. Schizophrenia Research. 2025. doi:10.1016/j.schres.2025.03.005

BibTeX
@article{Olasore2025,
  author = {Olasore, Holiness S A and Faleti, Joseph O and Afe, Taiwo O and Murtala, Abdullahi A and Olawale, Matthew O and Awesu, Abdur-Rasheed B and Igwo-Ezikpe, Miriam N and Magbagbeola, Olubunmi A and Olashore, Anthony A},
  title = {Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile},
  journal = {Schizophrenia Research},
  year = {2025},
  doi = {10.1016/j.schres.2025.03.005}
}
Kostenlos starten →